Doripenem: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Doripenem is an ultra-broad spectrum injectable [[antibiotic]]. It is a beta-lactam and belongs to the subgroup [[carbapenem]]. It was launched by[[Shionogi Co.]] of Japan under the [[brand name]] | Doripenem is an ultra-broad spectrum injectable [[antibiotic]]. It is a beta-lactam and belongs to the subgroup [[carbapenem]]. It was launched by[[Shionogi Co.]] of Japan under the [[brand name]] Finibax in 2005. It is particularly active against [[Pseudomonas aeruginosa]]. | ||
==Category== | ==Category== | ||
Carbapenem | Carbapenem | ||
==US Brand Names== | ==US Brand Names== | ||
DORIBAX<sup>®</sup> | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Doripenem description|Description]]''' | '''[[Doripenem description|Description]]''' | ||
Revision as of 02:34, 26 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup carbapenem. It was launched byShionogi Co. of Japan under the brand name Finibax in 2005. It is particularly active against Pseudomonas aeruginosa.
Category
Carbapenem
US Brand Names
DORIBAX®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages